OUTLOOK THERAPEUTICS, INC. (OTLK) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 28.68M USD | Liabilities, Current |
| Cash and equivalents | 11.24M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 5.04M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.68M | $11.24M | (m) | $1.64M | $5.04M | (m) |
| 2026-03-31 | (m) | $38.88M | $7.75M | (m) | $2.72M | $3.34M | (m) |
| 2025-12-31 | (m) | $49.06M | $8.68M | (m) | $114.61K | $3.46M | (m) |
| 2025-09-30 | (m) | $45.81M | $8.08M | (m) | $1.49M | $3.34M | (m) |
| 2025-06-30 | (m) | $31.49M | $8.90M | (m) | $1.75M | $4.13M | (m) |
| 2025-03-31 | (m) | $24.82M | $7.56M | (m) | (m) | $3.60M | (m) |
| 2024-12-31 | (m) | $48.24M | $5.70M | (m) | (m) | $3.11M | (m) |
| 2024-09-30 | (m) | $42.55M | $14.93M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $42.55M | $32.02M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $54.08M | $47.23M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $45.97M | $10.36M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $46.73M | $23.39M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $49.93M | $33.71M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $43.53M | $43.63M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $15.08M | $52.34M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $19.73M | $17.40M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $18.43M | $26.02M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $31.41M | $58.42M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $19.95M | $70.15M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $6.75M | $14.48M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $19.64M | $19.69M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $23.90M | $37.17M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.12M | $5.57M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $15.89M | $12.54M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $18.45M | $23.95M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $23.71M | $4.65M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $20.10M | $1.33M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $20.29M | $8.02M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $23.22M | $14.03M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $26.99M | $155.47K | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $27.54M | $227.72K | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $32.04M | $1.72M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $32.26M | $11.80M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $31.75M | $5.94M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $31.20M | $13.84M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $28.74M | $3.19M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $39.27M | $139.90K | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $34.78M | $81.05K | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $32.13M | $2.08M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $20.44M | $2.35M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $22.94M | $13.56M | (m) | $3.67K | (m) | (m) |
| 2016-03-31 | (m) | $35.98M | $2.84M | (m) | $504.86K | (m) | (m) |
| 2015-12-31 | (m) | (m) | $5.58M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $37.04M | $9.07M | (m) | $20.00K | (m) | (m) |
| 2015-06-30 | (m) | (m) | $5.38M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $425.82K | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $2.35M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |